Related Experiment Videos
Zidovudine therapy in children with acquired immunodeficiency syndrome
S Blanche1, M Caniglia, A Fischer
1Département de Pédiatrie, Hôpital Necker, Paris, France.
Insights
Zidovudine (azidothymidine) treatment in children with acquired immunodeficiency syndrome (AIDS) showed transient viral load reduction and variable clinical responses. Further studies are needed to optimize pediatric AIDS treatment regimens.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Immunology
Background:
- Acquired immunodeficiency syndrome (AIDS) in children presents unique challenges.
- Neurologic impairment is a significant complication in pediatric AIDS.
- Zidovudine (azidothymidine) is a key antiretroviral medication.
Purpose of the Study:
- To evaluate the efficacy and safety of zidovudine in children with AIDS.
- To assess the impact of zidovudine on viral markers and immune cell counts.
- To investigate the clinical and neurological outcomes in pediatric AIDS patients receiving zidovudine.
Main Methods:
- Eight children with AIDS (aged 4 months to 12 years) received intravenous then oral zidovudine for six months.
- Clinical status, neurological impairment, lymphocyte counts (CD4+), and p24 antigen levels were monitored.
- Human immunodeficiency virus (HIV) serology, including anti-core antibodies, was assessed.
Main Results:
- Transient decrease in p24 human immunodeficiency virus (HIV) serum antigens observed during intravenous therapy.
- Variable clinical responses, with dramatic improvement in two children and transient or no improvement in others.
- Increased CD4+ cell counts were transient; no significant change in in vitro lymphocyte proliferation.
- Hematologic toxicity was comparable to that seen in adults.
Conclusions:
- Zidovudine demonstrated transient efficacy in reducing viral markers in children with AIDS.
- Clinical and immunological responses were variable, highlighting the need for optimized pediatric treatment.
- Further research is essential to establish optimal zidovudine regimens for children with AIDS.
Abstract:
Eight children with acquired immunodeficiency syndrome (AIDS), aged four months to 12 years, were treated with zidovudine (azidothymidine) 100 mg/m2 intravenously every six hours for 14 days, followed by oral zidovudine at the same dose for a total of six months. Of the eight, six were infected at birth and two were contaminated by blood transfusion at ages eight and nine years, respectively; seven of the eight showed specific neurologic impairment consisting of encephalopathy (six children) and myelopathy (one child). In two children, a dramatic improvement of clinical status occurred, including neurologic progress in one; in three, the improvement was dissociate or transient and in the other three, no modification was observed. A marked increase of total lymphocyte and CD4(+) cell counts occurred in four children but was transient without modification of in vitro antigen-induced lymphocyte proliferation; p24 human immunodeficiency virus serum antigens were detected in seven of eight children, then transiently disappeared in all children during intravenous therapy but reappeared progressively during the oral regimen in all but one. Progressive modification of human immunodeficiency virus serology was noted in five children, mainly characterized by the finding of anti-core antibodies. The hematologic toxicity of zidovudine was comparable with that observed in adults. These preliminary results support the need for further studies in order to delineate the optimal regimen of zidovudine in children with AIDS.